Ken Griffin Nrx Pharmaceuticals, Inc. Call Options Transaction History

Citadel Advisors LLC

7 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q1 2024 May 15, 2024	SELL	$0.29 - $0.7 $16,559 - $39,970	-57,100 Reduced 64.89%	30,900 $14,000
Q4 2023 Feb 14, 2024	SELL	$0.26 - $0.47 $1,456 - $2,632	-5,600 Reduced 5.98%	88,000 $40,000
Q3 2023 Nov 14, 2023	BUY	$0.23 - $0.5 $1,357 - $2,950	5,900 Added 6.73%	93,600 $24,000
Q2 2023 Aug 14, 2023	SELL	$0.46 - $0.89 $276 - $534	-600 Reduced 0.68%	87,700 $42,000
Q1 2023 May 15, 2023	SELL	$0.66 - $1.4 $50,754 - $107,660	-76,900 Reduced 46.55%	88,300 $58,000
Q4 2022 Feb 14, 2023	SELL	$0.79 - $9.19 $24,332 - $283,052	-30,800 Reduced 15.71%	165,200 $183,000
Q3 2022 Nov 14, 2022	SELL	$0.2 - $8.07 $5,340 - $215,469	-26,700 Reduced 11.99%	196,000 $145,000

17.4K

Ticker NRXP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 67,641,296
Market Cap $111M
Description
NRX Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. Its products include ZYESAMI, an investigational drug that has completed a Phase IIb/III clinical study for COVID-19 related respiratory failure; and NRX-10...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.